• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PD-1 刺激激活 SHP2 的分子机制。

Molecular mechanism of SHP2 activation by PD-1 stimulation.

机构信息

Leibniz University Hannover, Institute of Organic Chemistry and Center for Biomolecular Drug Research, Schneiderberg 38, 30167 Hannover, Germany.

European Molecular Biology Laboratory, Structural and Computational Biology Unit, Meyerhofstrasse 1, 69117 Heidelberg, Germany.

出版信息

Sci Adv. 2020 Jan 31;6(5):eaay4458. doi: 10.1126/sciadv.aay4458. eCollection 2020 Jan.

DOI:10.1126/sciadv.aay4458
PMID:32064351
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6994217/
Abstract

In cancer, the programmed death-1 (PD-1) pathway suppresses T cell stimulation and mediates immune escape. Upon stimulation, PD-1 becomes phosphorylated at its immune receptor tyrosine-based inhibitory motif (ITIM) and immune receptor tyrosine-based switch motif (ITSM), which then bind the Src homology 2 (SH2) domains of SH2-containing phosphatase 2 (SHP2), initiating T cell inactivation. The SHP2-PD-1 complex structure and the exact functions of the two SH2 domains and phosphorylated motifs remain unknown. Here, we explain the structural basis and provide functional evidence for the mechanism of PD-1-mediated SHP2 activation. We demonstrate that full activation is obtained only upon phosphorylation of both ITIM and ITSM: ITSM binds C-SH2 with strong affinity, recruiting SHP2 to PD-1, while ITIM binds N-SH2, displacing it from the catalytic pocket and activating SHP2. This binding event requires the formation of a new inter-domain interface, offering opportunities for the development of novel immunotherapeutic approaches.

摘要

在癌症中,程序性死亡受体 1 (PD-1) 途径抑制 T 细胞的刺激并介导免疫逃逸。在受到刺激后,PD-1 在其免疫受体酪氨酸基抑制基序 (ITIM) 和免疫受体酪氨酸基开关基序 (ITSM) 上发生磷酸化,然后与含 SH2 结构域的磷酸酶 2 (SHP2) 的 SH2 结构域结合,启动 T 细胞失活。PD-1 介导的 SHP2 激活的 SHP2-PD-1 复合物结构和两个 SH2 结构域和磷酸化基序的确切功能仍不清楚。在这里,我们解释了 PD-1 介导的 SHP2 激活的结构基础,并提供了功能证据。我们证明,只有在 ITIM 和 ITSM 都磷酸化时才能获得完全激活:ITSM 与 C-SH2 具有很强的亲和力结合,将 SHP2 招募到 PD-1 上,而 ITIM 与 N-SH2 结合,将其从催化口袋中置换出来并激活 SHP2。这种结合事件需要形成一个新的域间界面,为开发新型免疫治疗方法提供了机会。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59a9/6994217/e74884fec410/aay4458-F6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59a9/6994217/4a1b1c0921e2/aay4458-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59a9/6994217/dae946745078/aay4458-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59a9/6994217/3b9c9e0df710/aay4458-F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59a9/6994217/a25115d2a780/aay4458-F4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59a9/6994217/03af9763f0c7/aay4458-F5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59a9/6994217/e74884fec410/aay4458-F6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59a9/6994217/4a1b1c0921e2/aay4458-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59a9/6994217/dae946745078/aay4458-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59a9/6994217/3b9c9e0df710/aay4458-F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59a9/6994217/a25115d2a780/aay4458-F4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59a9/6994217/03af9763f0c7/aay4458-F5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59a9/6994217/e74884fec410/aay4458-F6.jpg

相似文献

1
Molecular mechanism of SHP2 activation by PD-1 stimulation.PD-1 刺激激活 SHP2 的分子机制。
Sci Adv. 2020 Jan 31;6(5):eaay4458. doi: 10.1126/sciadv.aay4458. eCollection 2020 Jan.
2
H, C, N chemical shift assignments of SHP2 SH2 domains in complex with PD-1 immune-tyrosine motifs.SHP2 SH2 结构域与 PD-1 免疫酪氨酸基序复合物的 H、C、N 化学位移赋值。
Biomol NMR Assign. 2020 Oct;14(2):179-188. doi: 10.1007/s12104-020-09941-y. Epub 2020 Apr 1.
3
Exploring the Allosteric Mechanism of Src Homology-2 Domain-Containing Protein Tyrosine Phosphatase 2 (SHP2) by Molecular Dynamics Simulations.通过分子动力学模拟探索含Src同源2结构域蛋白酪氨酸磷酸酶2(SHP2)的变构机制
Front Chem. 2020 Nov 23;8:597495. doi: 10.3389/fchem.2020.597495. eCollection 2020.
4
Molecular recognition of ITIM/ITSM domains with SHP2 and their allosteric effect.ITIM/ITSM 结构域与 SHP2 的分子识别及其别构效应。
Phys Chem Chem Phys. 2024 Mar 20;26(12):9155-9169. doi: 10.1039/d3cp03923d.
5
Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation.SHP-2 SH2 结构域与 PD-1 ITSM 的相互作用诱导 PD-1 二聚化和 SHP-2 的激活。
Commun Biol. 2020 Mar 17;3(1):128. doi: 10.1038/s42003-020-0845-0.
6
Probing the Immunoreceptor Tyrosine-Based Inhibition Motif Interaction Protein Partners with Proteomics.用蛋白质组学方法探测免疫受体酪氨酸抑制基序相互作用蛋白的蛋白结合伙伴。
Molecules. 2024 Apr 25;29(9):1977. doi: 10.3390/molecules29091977.
7
Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors.免疫检查点受体对 SHP1/SHP2 结合的分子特征差异。
Elife. 2021 Nov 4;10:e74276. doi: 10.7554/eLife.74276.
8
Study on the allosteric activation mechanism of SHP2 elastic network models and neural relational inference molecular dynamics simulation.SHP2 变构激活机制的弹性网络模型与神经关系推理分子动力学模拟研究。
Phys Chem Chem Phys. 2023 Sep 13;25(35):23588-23601. doi: 10.1039/d3cp02795c.
9
Uncoupling ITIM receptor G6b-B from tyrosine phosphatases Shp1 and Shp2 disrupts murine platelet homeostasis.ITIM 受体 G6b-B 与酪氨酸磷酸酶 Shp1 和 Shp2 分离可破坏小鼠血小板稳态。
Blood. 2018 Sep 27;132(13):1413-1425. doi: 10.1182/blood-2017-10-802975. Epub 2018 Jun 11.
10
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.变构抑制 SHP2 磷酸酶可抑制受体酪氨酸激酶驱动的癌症。
Nature. 2016 Jul 7;535(7610):148-52. doi: 10.1038/nature18621. Epub 2016 Jun 29.

引用本文的文献

1
Anti-TIGIT therapies: a review of preclinical and clinical efficacy and mechanisms.抗TIGIT疗法:临床前及临床疗效与机制综述
Cancer Immunol Immunother. 2025 Jul 15;74(8):272. doi: 10.1007/s00262-025-04128-7.
2
Proximity-labeling proteomics reveals remodeled interactomes and altered localization of pathogenic SHP2 variants.邻近标记蛋白质组学揭示了致病性SHP2变体的重塑相互作用组和改变的定位。
bioRxiv. 2025 Mar 21:2025.02.26.640373. doi: 10.1101/2025.02.26.640373.
3
The pathogenic E139D mutation stabilizes a non-canonical active state of the multi-domain phosphatase SHP2.

本文引用的文献

1
SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade.SHP2抑制可触发抗肿瘤免疫并与PD-1阻断协同作用。
Acta Pharm Sin B. 2019 Mar;9(2):304-315. doi: 10.1016/j.apsb.2018.08.009. Epub 2018 Sep 5.
2
Phosphatases start shedding their stigma of undruggability.磷酸酶开始摆脱其不可成药的 stigma。 (这里“stigma”直译为“耻辱、污名”,结合语境可能表示“固有印象、负面标签”之类意思,可根据具体专业背景进一步优化表述)
Nat Rev Drug Discov. 2018 Nov 28;17(12):847-849. doi: 10.1038/nrd.2018.201.
3
Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition.
致病性E139D突变使多结构域磷酸酶SHP2的一种非典型活性状态得以稳定。
bioRxiv. 2025 Jul 4:2025.07.02.662799. doi: 10.1101/2025.07.02.662799.
4
Multiplexed single-cell transcriptomics reveals diverse phenotypic outcomes for pathogenic SHP2 variants.多重单细胞转录组学揭示了致病性SHP2变体的多种表型结果。
bioRxiv. 2025 Jul 2:2025.06.30.662374. doi: 10.1101/2025.06.30.662374.
5
Negative Immune Checkpoint Inhibitors.阴性免疫检查点抑制剂
Pharmaceutics. 2025 May 28;17(6):713. doi: 10.3390/pharmaceutics17060713.
6
The Role of LAIR1 as a Regulatory Receptor of Antitumor Immune Cell Responses and Tumor Cell Growth and Expansion.LAIR1作为抗肿瘤免疫细胞反应以及肿瘤细胞生长与增殖的调节性受体的作用。
Biomolecules. 2025 Jun 13;15(6):866. doi: 10.3390/biom15060866.
7
PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution.从鲨鱼到人类,程序性死亡受体1(PD-1)具有保守性:对PD-1、程序性死亡配体1(PD-L1)、程序性死亡配体2(PD-L2)和含Src同源2结构域蛋白磷酸酶2(SHP-2)进化的新见解
Front Immunol. 2025 May 28;16:1573492. doi: 10.3389/fimmu.2025.1573492. eCollection 2025.
8
Development of a Peptide Inhibitor Targeting the C-SH2 Domain of the SHP2 Phosphatase.靶向SHP2磷酸酶C-SH2结构域的肽抑制剂的开发
Chembiochem. 2025 May 27;26(10):e202400938. doi: 10.1002/cbic.202400938. Epub 2025 May 16.
9
Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy.重编程乳腺肿瘤免疫微环境:从冷到热的转变以增强免疫治疗
J Exp Clin Cancer Res. 2025 Apr 25;44(1):131. doi: 10.1186/s13046-025-03394-8.
10
Enhancing antitumor immunity: the role of immune checkpoint inhibitors, anti-angiogenic therapy, and macrophage reprogramming.增强抗肿瘤免疫力:免疫检查点抑制剂、抗血管生成疗法和巨噬细胞重编程的作用
Front Oncol. 2025 Apr 7;15:1526407. doi: 10.3389/fonc.2025.1526407. eCollection 2025.
致癌突变导致 SHP2 的结构重排及其对癌蛋白变构抑制抗性的影响。
Nat Commun. 2018 Oct 30;9(1):4508. doi: 10.1038/s41467-018-06823-9.
4
Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2.磷酸酶 SHP2 激活突变和别构药物抑制的作用机制。
Nat Commun. 2018 Oct 30;9(1):4507. doi: 10.1038/s41467-018-06814-w.
5
Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis.PD-1 或 PD-L1 抑制剂及 PD-L1 表达状态在癌症中的疗效:荟萃分析。
BMJ. 2018 Sep 10;362:k3529. doi: 10.1136/bmj.k3529.
6
Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo.Shp-2 在体内建立 T 细胞耗竭和 PD-1 信号传导方面是可有可无的。
Cell Rep. 2018 Apr 3;23(1):39-49. doi: 10.1016/j.celrep.2018.03.026.
7
Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor.PD-1 亲和纯化质谱分析揭示 SAP 作为一种新的检查点抑制剂。
Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):E468-E477. doi: 10.1073/pnas.1710437115. Epub 2017 Dec 27.
8
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.T细胞共刺激受体CD28是PD-1介导抑制作用的主要靶点。
Science. 2017 Mar 31;355(6332):1428-1433. doi: 10.1126/science.aaf1292. Epub 2017 Mar 9.
9
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.变构抑制 SHP2 磷酸酶可抑制受体酪氨酸激酶驱动的癌症。
Nature. 2016 Jul 7;535(7610):148-52. doi: 10.1038/nature18621. Epub 2016 Jun 29.
10
Nivolumab: targeting PD-1 to bolster antitumor immunity.纳武单抗:靶向程序性死亡受体1以增强抗肿瘤免疫力。
Future Oncol. 2015;11(9):1307-26. doi: 10.2217/fon.15.52. Epub 2015 Mar 23.